| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Silence Therapeutics plc (NASDAQ: SLN)
SLN Technical Analysis
5
| As on 9th Jun 2023 SLN STOCK Price closed @ 5.92 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 14.26 & Strong Sell for SHORT-TERM with Stoploss of 21.45 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SLNSTOCK Price
| Open | 5.83 | Change | Price | % |
| High | 6.22 | 1 Day | 0.12 | 2.07 |
| Low | 5.58 | 1 Week | 0.20 | 3.50 |
| Close | 5.92 | 1 Month | 1.30 | 28.14 |
| Volume | 175233 | 1 Year | -17.86 | -75.11 |
| 52 Week High 24.74 | 52 Week Low 4.61 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| SLN Daily Charts |
SLN Intraday Charts |
Whats New @ Bazaartrend |
SLN Free Analysis |
|
|
SLN Important Levels Intraday
| RESISTANCE | 7.15 |
| RESISTANCE | 6.76 |
| RESISTANCE | 6.51 |
| RESISTANCE | 6.27 |
| SUPPORT | 5.57 |
| SUPPORT | 5.33 |
| SUPPORT | 5.08 |
| SUPPORT | 4.69 |
SLN Forecast May 2024
| 4th UP Forecast | 19.27 |
| 3rd UP Forecast | 14.99 |
| 2nd UP Forecast | 12.34 |
| 1st UP Forecast | 9.7 |
| 1st DOWN Forecast | 2.14 |
| 2nd DOWN Forecast | -0.5 |
| 3rd DOWN Forecast | -3.15 |
| 4th DOWN Forecast | -7.43 |
SLN Weekly Forecast
| 4th UP Forecast | 12.32 |
| 3rd UP Forecast | 10.27 |
| 2nd UP Forecast | 9.00 |
| 1st UP Forecast | 7.73 |
| 1st DOWN Forecast | 4.11 |
| 2nd DOWN Forecast | 2.84 |
| 3rd DOWN Forecast | 1.57 |
| 4th DOWN Forecast | -0.48 |
SLN Forecast2024
| 4th UP Forecast | 47.95 |
| 3rd UP Forecast | 34.47 |
| 2nd UP Forecast | 26.14 |
| 1st UP Forecast | 17.81 |
| 1st DOWN Forecast | -5.97 |
| 2nd DOWN Forecast | -14.3 |
| 3rd DOWN Forecast | -22.63 |
| 4th DOWN Forecast | -36.11 |
Silence Therapeutics plc ( NASDAQ USA Symbol : SLN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SLN Business Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom. Address: 72 Hammersmith Road, London, United Kingdom, W14 8TH
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service